div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: and Immunologydr_raghunew · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms The oncogenic potential of multimodality therapy might src=https:reader033fdocumentsinreader033viewer20220420055e6fa72496c9e0651d683699html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: and Immunologydr_raghunew · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms The oncogenic potential of multimodality therapy might src=https:reader033fdocumentsinreader033viewer20220420055e6fa72496c9e0651d683699html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: and Immunologydr_raghunew · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms The oncogenic potential of multimodality therapy might src=https:reader033fdocumentsinreader033viewer20220420055e6fa72496c9e0651d683699html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: and Immunologydr_raghunew · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms The oncogenic potential of multimodality therapy might src=https:reader033fdocumentsinreader033viewer20220420055e6fa72496c9e0651d683699html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdiv